Compare Nike Inc (NKE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Nike Inc trades at $41.3 (market cap $61.30B), while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Nike Inc pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| NKE | REGN | |
|---|---|---|
Market Cap | $61.30B | $82.06B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $79.17 | $812.27 |
52-Week Low | $40.75 | $555.51 |
Enterprise Value | $63.30B | $76.77B |
Dividend Yield | 3.97% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $42.11, up 0.98% on the day, showing resilience amid a challenging period. The stock faces bearish technical signals but maintains strong profitability metrics including 42.91% gross margin and 22.14% ROE. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.72 significantly exceeding the $0.11 forecast. However, revenue declined to $46.31B in 2025 from $51.4B in 2024, reflecting ongoing business headwinds.
Nike's investment case balances strong brand value and consistent earnings beats against revenue pressures and competitive challenges. The consensus price target of $50.45 suggests 20% upside potential, though technical indicators remain bearish. Key risks include China market weakness and inventory management issues, while opportunities lie in digital transformation and product innovation driving future growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
